Trial Profile
A Preoperative Biological Trial of Cetuximab, Dasatinib or the Combination in Colorectal Cancer Patients with Resectable Liver Metastases
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Dasatinib (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Biomarker; Pharmacodynamics
- Acronyms SPORE
- 12 Jan 2010 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.
- 12 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 04 Feb 2009 New trial record